Coya Therapeutics Inc.
Organization details
- Legal name
- Coya Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- COYA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001835022
Board of directors
-
Anabella Villalobos · DirectorSince 2023
-
Ann Lee · DirectorSince 2023
-
Arun Swaminathan · Director · Chief Executive OfficerSince 2024
-
Dieter Weinand · DirectorSince 2023
-
Dov A. Goldstein M.D. · DirectorSince 2023
-
Hideki Garren · DirectorSince 2023
-
Howard Berman · Director · Executive ChairmanSince 2023
-
Mark H. Pavao · DirectorSince 2026
-
Wilbur L. Ross Jr. · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 25, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.2%
Board connections
3 of this board's directors also sit on 3 other boards. 3 are in the same sector.
-
Atea Pharmaceuticals Inc. Same sectorvia Howard Berman
-
Gain Therapeutics Inc. Same sectorvia Dov A. Goldstein M.D.
-
Replimune Group Inc. Same sectorvia Dieter Weinand
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2025 | Dov A. Goldstein M.D. Director | Option exercise | +17,557 | $1.09 | $19,137 |
| Nov 14, 2024 | SNYDER DAVID S Officer (Chief Financial Officer) | Open-market purchase | +1,800 | $7.19 | $12,942 |
| Nov 13, 2024 | Arun Swaminathan Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $7.36 | $36,800 |
| Nov 11, 2024 | Grossman Fred Officer (Chief Medical Officer) | Open-market purchase | +2,710 | $7.37 | $19,973 |
| Nov 11, 2024 | Arun Swaminathan Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $7.34 | $36,700 |
| Aug 22, 2023 | Ann Lee Director | Open-market purchase | +1,000 | $3.62 | $3,620 |
| Jan 3, 2023 | Howard Berman Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Ann Lee Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Hepner Adrian Officer (Chief Medical Officer) | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Hideki Garren Director | Open-market purchase | +2,000 | — | — |
| Jan 3, 2023 | SNYDER DAVID S Officer (Chief Financial Officer) | Open-market purchase | +7,000 | — | — |
| Jan 3, 2023 | Anabella Villalobos Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Dov A. Goldstein M.D. Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Ann Lee Director | Derivative conversion | +6,479 | $4.00 | $25,916 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Coya Therapeutics Inc.
Who is the CEO of Coya Therapeutics Inc.?
Howard Berman is Coya Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Coya Therapeutics Inc.'s board?
Coya Therapeutics Inc.'s board has 9 directors: Anabella Villalobos, Ann Lee, Arun Swaminathan, Dieter Weinand, Dov A. Goldstein M.D., Hideki Garren, Howard Berman, Mark H. Pavao and Wilbur L. Ross Jr.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="coya-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.